These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1078 related items for PubMed ID: 7540696
1. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Mayordomo JI, Rivera F, Díaz-Puente MT, Lianes P, Colomer R, López-Brea M, López E, Paz-Ares L, Hitt R, García-Ribas I. J Natl Cancer Inst; 1995 Jun 07; 87(11):803-8. PubMed ID: 7540696 [Abstract] [Full Text] [Related]
2. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. García-Carbonero R, Mayordomo JI, Tornamira MV, López-Brea M, Rueda A, Guillem V, Arcediano A, Yubero A, Ribera F, Gómez C, Trés A, Pérez-Gracia JL, Lumbreras C, Hornedo J, Cortés-Funes H, Paz-Ares L. J Natl Cancer Inst; 2001 Jan 03; 93(1):31-8. PubMed ID: 11136839 [Abstract] [Full Text] [Related]
3. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Ravaud A, Chevreau C, Cany L, Houyau P, Dohollou N, Roché H, Soubeyran P, Bonichon F, Mihura J, Eghbali H, Tabah I, Bui BN. J Clin Oncol; 1998 Sep 03; 16(9):2930-6. PubMed ID: 9738560 [Abstract] [Full Text] [Related]
4. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. J Clin Oncol; 2004 Aug 15; 22(16):3350-6. PubMed ID: 15310780 [Abstract] [Full Text] [Related]
5. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G. N Engl J Med; 1991 Jul 18; 325(3):164-70. PubMed ID: 1711156 [Abstract] [Full Text] [Related]
10. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy. Skoetz N, Bohlius J, Engert A, Monsef I, Blank O, Vehreschild JJ. Cochrane Database Syst Rev; 2015 Dec 21; 2015(12):CD007107. PubMed ID: 26687844 [Abstract] [Full Text] [Related]
11. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma. Dinçol D, Samur M, Pamir A, Sencan O, Akbulut H, Yalçin B, Onur H, Demirkazik A, Senler FC, Içli F. Cancer; 2000 May 01; 88(9):2033-6. PubMed ID: 10813713 [Abstract] [Full Text] [Related]
12. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Wong SF, Chan HO. Pharmacotherapy; 2005 Mar 01; 25(3):372-8. PubMed ID: 15843284 [Abstract] [Full Text] [Related]
13. [Prevention and treatment of febrile neutropenia]. Montemurro F, Gallicchio M, Aglietta M. Tumori; 1997 Mar 01; 83(2 Suppl):S15-9. PubMed ID: 9235724 [Abstract] [Full Text] [Related]
14. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. Thomas X, Boiron JM, Huguet F, Reman O, Sutton L, Turlure P, Garban F, Gardin C, Espinouse D, Boulat O, Lhéritier V, Fiere D, Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group). Hematol J; 2004 Mar 01; 5(5):384-94. PubMed ID: 15448664 [Abstract] [Full Text] [Related]
15. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. Nichols CR, Fox EP, Roth BJ, Williams SD, Loehrer PJ, Einhorn LH. J Clin Oncol; 1994 Jun 01; 12(6):1245-50. PubMed ID: 7515413 [Abstract] [Full Text] [Related]
16. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Bohlius J, Reiser M, Schwarzer G, Engert A. Cochrane Database Syst Rev; 2004 Jun 01; (3):CD003189. PubMed ID: 15266474 [Abstract] [Full Text] [Related]
17. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. Yau JC, Neidhart JA, Triozzi P, Verma S, Nemunaitis J, Quick DP, Mayernik DG, Oette DH, Haynes FA, Holcenberg J. Am J Hematol; 1996 Apr 01; 51(4):289-95. PubMed ID: 8602629 [Abstract] [Full Text] [Related]
19. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. Ozkaynak MF, Krailo M, Chen Z, Feusner J. Pediatr Blood Cancer; 2005 Sep 01; 45(3):274-80. PubMed ID: 15806544 [Abstract] [Full Text] [Related]
20. Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia. Siddiqui T, Burney IA, Kakepoto GN, Khurshid M, Salam A, Smego RA. J Pak Med Assoc; 2002 May 01; 52(5):206-10. PubMed ID: 12174492 [Abstract] [Full Text] [Related] Page: [Next] [New Search]